BACKGROUND:Beta blocker treatment may worsen glucose metabolism. OBJECTIVE: To study the development of new onset diabetes in a large cohort of patients with heart failure treated with eithermetoprolol or carvedilol. DESIGN: Prospective and retrospective analysis of a controlled clinical trial. SETTING: Multinational multicentre study. PATIENTS: 3029 patients with chronic heart failure. INTERVENTIONS: Randomly assigned treatment with carvedilol (n = 1511, target dose 50 mg daily) or metoprolol tartrate (n = 1518, target dose 100 mg daily). RESULTS:Diabetic events (diabetic coma, peripheral gangrene, diabetic foot, decreased glucose tolerance or hyperglycaemia) and new onset diabetes (clinical diagnosis, repeated high random glucose level or glucose lowering drugs) were assessed in 2298 patients without diabetes at baseline. Diabetic events occurred in 122/1151 (10.6%) patients in the carvedilol group and 149/1147 (13.0%) patients in the metoprolol group (hazard ratio (HR) = 0.78; 95% confidence interval (CI) 0.61 to 0.99; p = 0.039). New onset diabetes was diagnosed in 119/1151 (10.3%) v 145/1147 (12.6%) cases in the carvedilol and metoprolol treatment groups (HR = 0.78, CI 0.61 to 0.997; p = 0.048), respectively. Patients with diabetes at baseline had an increased mortality compared with non-diabetic subjects (45.3% v 33.9%; HR = 1.45, CI 1.28 to 1.65). Both diabetic and non-diabetic subjects at baseline had a similar reduction in mortality with carvedilol compared with metoprolol (RR = 0.85; CI 0.69 to 1.06 and RR = 0.82; CI 0.71 to 0.94, respectively). CONCLUSION: A high prevalence and incidence of diabetes is found in patients with heart failure over a course of 5 years. New onset diabetes is more likely to occur during treatment with metoprolol than during treatment with carvedilol.
RCT Entities:
BACKGROUND: Beta blocker treatment may worsen glucose metabolism. OBJECTIVE: To study the development of new onset diabetes in a large cohort of patients with heart failure treated with either metoprolol or carvedilol. DESIGN: Prospective and retrospective analysis of a controlled clinical trial. SETTING: Multinational multicentre study. PATIENTS: 3029 patients with chronic heart failure. INTERVENTIONS: Randomly assigned treatment with carvedilol (n = 1511, target dose 50 mg daily) or metoprolol tartrate (n = 1518, target dose 100 mg daily). RESULTS:Diabetic events (diabetic coma, peripheral gangrene, diabetic foot, decreased glucose tolerance or hyperglycaemia) and new onset diabetes (clinical diagnosis, repeated high random glucose level or glucose lowering drugs) were assessed in 2298 patients without diabetes at baseline. Diabetic events occurred in 122/1151 (10.6%) patients in the carvedilol group and 149/1147 (13.0%) patients in the metoprolol group (hazard ratio (HR) = 0.78; 95% confidence interval (CI) 0.61 to 0.99; p = 0.039). New onset diabetes was diagnosed in 119/1151 (10.3%) v 145/1147 (12.6%) cases in the carvedilol and metoprolol treatment groups (HR = 0.78, CI 0.61 to 0.997; p = 0.048), respectively. Patients with diabetes at baseline had an increased mortality compared with non-diabetic subjects (45.3% v 33.9%; HR = 1.45, CI 1.28 to 1.65). Both diabetic and non-diabetic subjects at baseline had a similar reduction in mortality with carvedilol compared with metoprolol (RR = 0.85; CI 0.69 to 1.06 and RR = 0.82; CI 0.71 to 0.94, respectively). CONCLUSION: A high prevalence and incidence of diabetes is found in patients with heart failure over a course of 5 years. New onset diabetes is more likely to occur during treatment with metoprolol than during treatment with carvedilol.
Authors: Marco Metra; Christian Torp-Pedersen; Karl Swedberg; John G F Cleland; Andrea Di Lenarda; Michel Komajda; Willem J Remme; Beatrix Lutiger; Armin Scherhag; Mary Ann Lukas; Andrew Charlesworth; Philip A Poole-Wilson Journal: Eur Heart J Date: 2005-07-21 Impact factor: 29.983
Authors: Philip A Poole-Wilson; John G F Cleland; Andrea Di Lenarda; Peter Hanrath; Michel Komajda; Marco Metra; Willem J Remme; Karl Swedberg; Christian Torp-Pedersen Journal: Eur J Heart Fail Date: 2002-06 Impact factor: 15.534
Authors: Prakash C Deedwania; Thomas D Giles; Michael Klibaner; Jalal K Ghali; Johan Herlitz; Per Hildebrandt; John Kjekshus; Jindrich Spinar; Jiri Vitovec; Hilary Stanbrook; John Wikstrand Journal: Am Heart J Date: 2005-01 Impact factor: 4.749
Authors: Christian Torp-Pedersen; Philip A Poole-Wilson; Karl Swedberg; John G F Cleland; Andrea Di Lenarda; Peter Hanrath; Michel Komajda; Beatrix Lutiger; Marco Metra; Willem J Remme; Armin Scherhag; Allan Skene Journal: Am Heart J Date: 2005-02 Impact factor: 4.749
Authors: N Suskin; R S McKelvie; R J Burns; R Latini; D Pericak; J Probstfield; J L Rouleau; C Sigouin; C B Solymoss; R Tsuyuki; M White; S Yusuf Journal: Eur Heart J Date: 2000-08 Impact factor: 29.983
Authors: M Packer; A J Coats; M B Fowler; H A Katus; H Krum; P Mohacsi; J L Rouleau; M Tendera; A Castaigne; E B Roecker; M K Schultz; D L DeMets Journal: N Engl J Med Date: 2001-05-31 Impact factor: 91.245
Authors: Orly Vardeny; Gabriel Nicholas; Alina Andrei; Kevin A Buhr; Matt P Hermanson; John J Moran; Michelle A Detry; James H Stein Journal: Am J Hypertens Date: 2012-05-31 Impact factor: 2.689
Authors: Suzanne V Arnold; Joshua M Stolker; Kasia J Lipska; Philip G Jones; John A Spertus; Darren K McGuire; Silvio E Inzucchi; Abhinav Goyal; Thomas M Maddox; Marcus Lind; Divya Gumber; Supriya Shore; Mikhail Kosiborod Journal: Circ Cardiovasc Qual Outcomes Date: 2015-04-21
Authors: Britt Kveiborg; Thomas S Hermann; Atheline Major-Pedersen; Buris Christiansen; Christian Rask-Madsen; Jakob Raunsø; Lars Køber; Christian Torp-Pedersen; Helena Dominguez Journal: Cardiovasc Diabetol Date: 2010-05-25 Impact factor: 9.951